BAG Dres. med. Quist PartG

The research at BAG Dres. med. Quist PartG targets immune‑mediated disorders, with a primary focus on hidradenitis suppurativa, a chronic inflammatory condition that often resists standard anti‑TNF therapy.

• Evaluation of JAK inhibition as a new treatment approach
• Investigation of oral agents for refractory disease
• Safety monitoring in patients with prior biologic exposure

The Mainz site collaborates with academic partners to expand therapeutic options for patients who have limited responses to existing therapies.

Studies conducted at the Mainz location concentrate on moderate‑to‑severe hidradenitis suppurativa within the broader category of skin and connective tissue diseases, aiming to discover effective interventions for this challenging disease.

• Dose‑response exploration of the investigational compound LAD191
• Comparative efficacy versus placebo in a controlled setting
• Long‑term tolerability and safety assessments

With a single dedicated investigator, the site ensures meticulous oversight and rapid progress in advancing treatment strategies.